Sato Toshiyuki, Sato Masaaki, Nagai Kouhei, Fukasawa Masahiko, Nagashima Yoshiaki, Uchida Teisuke, Tsutiya Atsuhiro, Omoteyama Kazuki, Arito Mitsumi, Takakuwa Yukiko, Ooka Seido, Suematsu Naoya, Kawahata Kimito, Yamano Yoshihisa, Kato Tomohiro, Kurokawa Manae S
Clinical Proteomics and Molecular Medicine, St. Marianna University Graduate School of Medicine, Kawasaki, Kanagawa, Japan.
Department of Genetic Engineering, Faculty of Biology-Oriented Science and Technology, Kindai University, Kinokawa, Wakayama, Japan.
J Mass Spectrom Adv Clin Lab. 2025 Apr 30;37:28-38. doi: 10.1016/j.jmsacl.2025.04.001. eCollection 2025 Aug.
Relapsing polychondritis (RP) is an intractable disease characterized by recurrent inflammation of cartilaginous tissue throughout the body. It is difficult to accurately diagnose RP, and no useful biomarkers have yet been identified.
We analyzed serum peptide profiles to identify novel candidate biomarkers for RP.
Thirty-seven patients with RP, 42 patients with rheumatoid arthritis (RA), and 35 healthy control (HC) subjects were divided into training and testing sets. Seven patients demonstrating granulomatosis with polyangiitis (GPA) were used for validation. The ion intensity of serum peptides was comprehensively measured by matrix-assisted laser desorption/ionization time-of-flight/time-of-flight mass spectrometry and applied to a supervised multivariate analysis. Peptides of interest were analyzed by liquid chromatography-tandem mass spectrometry.
In the training set, models developed based on 11 (RP/HC-11P model), 9 (RP/RA-9P model), and 14 (RP/nonRP-14P model) peptides, out of 160 peptides detected were able to completely discriminate the RP group from the HC, RA, and nonRP (HC + RA) groups. Almost all of the 15 identified discriminatory peptides comprising these models were fragments of proteins associated with coagulation. Four models, each consisting of 4 out of 10 identified peptides of the RP/nonRP-14P model (models RP/nonRP-4P-2, -10, -11, and -38), provided ≥ 70.0 % sensitivity and specificity when applied to the validation set (the testing set and the GPA group) (AUROC, 0.779-0.815). Notably, the RP/nonRP-4P-2 model provided 83.3 % sensitivity and 71.7 % specificity in the validation set (AUROC, 0.802).
Serum peptides are useful as candidate biomarkers for discriminating RP and may be involved in the pathophysiology of RP.
复发性多软骨炎(RP)是一种难治性疾病,其特征为全身软骨组织反复发生炎症。准确诊断RP存在困难,目前尚未发现有用的生物标志物。
我们分析血清肽谱以鉴定RP的新型候选生物标志物。
37例RP患者、42例类风湿关节炎(RA)患者和35例健康对照(HC)受试者被分为训练集和测试集。7例患有肉芽肿性多血管炎(GPA)的患者用于验证。通过基质辅助激光解吸/电离飞行时间/飞行时间质谱全面测量血清肽的离子强度,并应用于监督多变量分析。通过液相色谱-串联质谱分析感兴趣的肽。
在训练集中,基于检测到的160种肽中的11种(RP/HC-11P模型)、9种(RP/RA-9P模型)和14种(RP/nonRP-14P模型)肽开发的模型能够将RP组与HC、RA和非RP(HC + RA)组完全区分开来。构成这些模型的15种已鉴定的鉴别肽中,几乎所有都是与凝血相关的蛋白质片段。RP/nonRP-14P模型中10种已鉴定肽中的4种组成的4个模型(RP/nonRP-4P-2、-10、-11和-38模型)应用于验证集(测试集和GPA组)时,灵敏度和特异性≥70.0%(曲线下面积,0.779 - 0.815)。值得注意的是,RP/nonRP-4P-2模型在验证集中的灵敏度为83.3%,特异性为71.7%(曲线下面积,0.802)。
血清肽可作为鉴别RP的候选生物标志物,可能参与RP的病理生理过程。